Welcome to our dedicated page for Jazz Pharmaceuticals Plc news (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals Plc stock.
Jazz Pharmaceuticals Plc (NASDAQ: JAZZ) is a global biopharmaceutical leader developing life-changing therapies for complex conditions in oncology, neuroscience, and sleep medicine. This dedicated news hub provides investors and healthcare professionals with timely updates on corporate milestones, regulatory developments, and clinical research advancements.
Our curated collection features official press releases, earnings reports, and analysis of strategic initiatives. Users can track key updates including FDA regulatory decisions, clinical trial results, and therapeutic portfolio expansions. The resource prioritizes accuracy and comprehensiveness, serving as a primary source for understanding Jazz's market position.
Content spans multiple categories essential for informed decision-making: product approvals, research collaborations, financial performance, and manufacturing updates. Each entry maintains strict editorial standards to ensure relevance to both clinical and investment communities.
Bookmark this page for streamlined access to Jazz Pharmaceuticals' latest developments. Check regularly for updates on innovative therapies addressing narcolepsy, epilepsy, and hematologic malignancies, supported by the company's established R&D expertise.
Jazz Pharmaceuticals, a purpose-led, people-centric company, emphasizes employee engagement and cultivating a unique culture. The company's approach includes:
1. Continuous listening through surveys, focus groups, and town halls, with 2023 Pulse surveys showing 85% of employees feel connected to the company's purpose and 81% recommend Jazz as a good place to work.
2. Diversity, Equity, Inclusion, and Belonging (DEIB) initiatives to create a workplace where everyone can be their authentic selves.
3. Employee Resource Teams (ConcERTos) and Affinity Forums to foster inclusivity and provide spaces for underrepresented groups and allies.
These efforts aim to create a welcoming environment, drive better business outcomes, and enable employees to do their best work in transforming patients' lives.
Jazz Pharmaceuticals presented updated Phase 2 data for zanidatamab, a dual HER2-targeted bispecific antibody, in combination with chemotherapy for HER2-positive metastatic gastroesophageal adenocarcinoma (mGEA) at ESMO 2024. Key findings include:
- Confirmed objective response rate (cORR) of 84%
- Median duration of response of 18.7 months
- Median progression-free survival (mPFS) of 15.2 months
- Kaplan-Meier–estimated 30-month overall survival of 59%
The safety profile remained manageable with no new safety signals. Jazz continues to enroll patients in the Phase 3 HERIZON-GEA-01 trial, with top-line data expected in Q2 2025.
Jazz Pharmaceuticals (Nasdaq: JAZZ) will present five abstracts at the European Society for Medical Oncology (ESMO) Congress 2024 from September 13-17 in Barcelona, Spain. Key highlights include:
1. New and updated data from a Phase 2 trial of zanidatamab, an investigational dual HER2-targeted bispecific antibody, in combination with chemotherapy for first-line treatment of HER2-positive metastatic gastroesophageal adenocarcinoma (mGEA).
2. Data from a Phase 2 study of zanidatamab combined with chemotherapy and bevacizumab as first-line treatment in HER2-positive metastatic colorectal cancer.
3. Findings from a Phase 2 trial evaluating Zepzelca® (lurbinectedin) and irinotecan in relapsed small cell lung cancer (SCLC) patients.
The company expects results from a Phase 3 clinical trial of zanidatamab in GEA in Q2 2025, potentially supporting global regulatory submissions.
Jazz Pharmaceuticals (Nasdaq: JAZZ) will present eight abstracts at the 15th European Epilepsy Congress (EEC) in Rome, Italy, from September 7-11, 2024. The presentations focus on Epidiolex/Epidyolex (cannabidiol) and its effects on patients with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS).
Key highlights include:
- BECOME Caregiver Survey results showing improvements in seizure frequency (87%), severity (81%), and non-seizure outcomes in patients using Epidyolex with clobazam
- Post-hoc analysis of GWPCARE3 and GWPCARE4 trials demonstrating clinically meaningful reductions in drop seizures for LGS patients
- Real-world data suggesting high rates of initial misdiagnosis in LGS and DS patients
- Analysis of ketogenic diet effects on cannabidiol plasma concentration and seizure reduction
The presentations aim to build scientific evidence supporting Epidyolex's holistic impact on patients, families, and caregivers.
Jazz Pharmaceuticals announced the pricing of $850 million in 3.125% exchangeable senior notes due 2030, with an option for an additional $150 million. The notes, issued by Jazz Investments I , will mature on September 15, 2030, with a 3.125% annual interest rate. The initial exchange rate is 6.5339 ordinary shares per $1,000 principal amount, equivalent to $153.05 per share. Jazz expects $833.7 million in net proceeds, planning to use $350 million to prepay term loans. Concurrently, Jazz repurchased $150 million of its ordinary shares at $109.32 per share.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced that its subsidiary, Jazz Investments I , plans to offer $850 million in exchangeable senior notes due 2030 to qualified institutional buyers. The notes will be exchangeable under certain conditions, with the option to settle in cash, ordinary shares, or a combination. Jazz intends to use the proceeds to prepay up to $350 million of term loans and for general corporate purposes. Additionally, Jazz expects to repurchase up to $150 million of its ordinary shares concurrently with the offering. The notes will be unsecured obligations, guaranteed by Jazz Pharmaceuticals, and will rank pari passu with existing 2026 notes but subordinate to secured debts.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced top-line results from a Phase 3 trial in Japan evaluating cannabidiol oral solution (Epidiolex/Epidyolex) for treating seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. The trial did not meet its primary efficacy endpoint of reducing seizure frequency compared to baseline in Japanese pediatric patients. However, numeric improvements were observed in primary and secondary endpoints, and no new safety signals were identified.
Despite not meeting the primary endpoint, Jazz remains confident in Epidyolex's clinical profile, citing its success in five previous Phase 3 trials involving over 900 patients globally. The company plans to continue collecting data and engage with Japanese regulatory authorities regarding a potential new drug application.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced its participation in two upcoming investor conferences in September 2024. The company will be present at the Wells Fargo Healthcare Conference on September 4, with a fireside chat at 7:15 a.m. PT, and the Bank of America Global Healthcare Conference on September 18, with a fireside chat at 7:55 a.m. PT.
Audio webcasts of both events will be available on the Jazz Pharmaceuticals website's Investors section, with replays archived for 30 days. Jazz Pharmaceuticals is a global biopharma company focused on developing life-changing medicines for serious diseases, with a portfolio including therapies for sleep disorders, epilepsy, and cancer. The company is headquartered in Dublin, Ireland, with operations and employees worldwide.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced their Q2 2024 financial results and updated 2024 guidance. Key growth drivers such as Xywav, Epidiolex, and Rylaze contributed to a 15% YoY revenue increase. Oncology revenues grew by 10% YoY. The company narrowed its 2024 revenue guidance to $4.0-$4.1 billion and affirmed GAAP and non-GAAP adjusted net income guidance. Key highlights include:
- Xywav sales grew by 13% YoY.
- Epidiolex/Epidyolex sales increased by 22% YoY.
- Rylaze sales rose by 6% YoY.
Other updates include the FDA's Priority Review for zanidatamab with a PDUFA date of Nov. 29, 2024, and significant pipeline catalysts expected through 2025. Financial highlights for Q2 2024 include a GAAP net income of $168.6 million ($2.49 per diluted share) and non-GAAP adjusted net income of $364.7 million ($5.30 per diluted share). The company also authorized a new $500 million share repurchase program and completed a repricing of $2.7 billion in term loans, anticipating $23 million in annual interest savings.
Jazz Pharmaceuticals (Nasdaq: JAZZ) announced the election of Laura Hamill to its Board of Directors at the Annual General Meeting. Ms. Hamill, a 35-year pharmaceutical industry veteran, brings extensive executive leadership and global commercial operations expertise. Shareholders also re-elected Kenneth O'Keefe and Mark Smith, while Patrick Kennedy was appointed earlier this year.
Ms. Hamill previously served as Executive Vice President of Worldwide Commercial Operations at Gilead Sciences and held various executive positions at Amgen Inc. She currently serves on the boards of Y-mAbs Therapeutics, BB Biotech, and Unchained Labs. The election reflects Jazz's focus on Board renewal, with five new directors appointed in the past five years. Peter Gray and Catherine Sohn have retired from the Board, which now comprises twelve directors.
FAQ
What is the current stock price of Jazz Pharmaceuticals Plc (JAZZ)?
What is the market cap of Jazz Pharmaceuticals Plc (JAZZ)?
